{"id":"W2339311613","doi":"10.1016/s1470-2045(16)30033-x","title":"Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1175,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Ottawa Hospital; McGill University","funders":"European Society for Medical Oncology; Boehringer Ingelheim","keywords":"Afatinib; Gefitinib; Medicine; Internal medicine; Lung cancer; Oncology; Population; Clinical endpoint; Randomized controlled trial; Epidermal growth factor receptor; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04042620639566981,"score_gpt":0.4065506950648967,"score_spread":0.3661244886692269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}